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sented significant improvement in all measured functional 
and histopathological parameters.  Conclusion: These find-
ings suggest that EA-MO had beneficial effects on CKD. This 
effect was probably achieved by the modulation of the renal 
sympathetic nerve activity and nitric oxide levels, leading to 
decreased blood pressure, which is associated with less pro-
teinuria.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Although there have been many advances in the un-
derstanding of the pathophysiology of chronic kidney 
disease (CKD), the number of patients suffering from this 
disease is growing, and the demand for renal replacement 
therapy is increasing. Efforts employed against CKD can-
not prevent progression of the disease, which culminates 
in end-stage disease despite application of the appropriate 
therapies  [1] . Therefore, novel concepts and approaches 
are needed.
 Over the last few decades, medical treatments based 
on traditional Chinese medicine (TCM) often rely on a 
combination of needle insertion and thermal stimula-
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 Abstract 
 Background/Aim: Chronic kidney disease (CKD) is an in-
creasing major public health problem worldwide. The sym-
pathetic nervous system and nitric oxide play an important 
role in the pathogenesis of CKD. Traditional Chinese medi-
cine has accumulated thousands of years of therapeutic ex-
periences. Electroacupuncture (EA) and moxibustion (MO) 
are two such therapeutic strategies. The aim of this study 
was to investigate the renal and hemodynamic effects of
EA-MO in an experimental model of a CKD.  Methods:  Male 
Wistar rats submitted to 5/6th nephrectomy (5/6 NX) were 
studied for 8 weeks. There were four groups: (1) control, nor-
mal rats; (2) NX, 5/6 NX only; (3) NX-AS, 5/6 NX and EA-MO 
session using sham points, and (4) NX-AM, 5/6 NX and EA-MO 
session using real acupoints. Biochemical and blood pres-
sure studies, renal sympathetic nerve activity measure-
ments, nitric oxide levels and the histopathological indices 
were assessed.  Results: The EA- and MO-treated group pre-
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tion to achieve results; the efficacy of such practices is 
increasingly recognized worldwide  [2–4] . Electroacu-
puncture (EA) is the electrical stimulation of acupoints 
using acupuncture needles and a short current pulse at 
various frequencies  [5] . Moxibustion (MO) is a technique 
that applies heat to acupoints by means of burning a 
compressed, powdered, combustible mass obtained from 
the young leaves of Eurasian artemisia  (Artemisia vul-
garis)  [6, 7] .
 EA is increasingly accepted as a viable therapy for 
treating a variety of diseases and has been used to im-
prove visceral autonomic malfunctions  [5, 8] . EA and 
MO stimulation have been used to modulate autonomic 
nervous activity, neurotransmitter levels, endogenous 
substance levels, levels of inflammatory factors and car-
diovascular and renal function. It has also been used to 
treat mild to moderate hypertension  [8–10] .
 CKD is becoming a worldwide public health problem 
 [11] . The relevant pathogenetic factors contributing to 
the progression of CKD include high blood pressure, 
neurogenic factors and the decreased production of ni-
tric oxide (NO)  [12, 13] . CKD may develop as a conse-
quence of chronic hypertension and may also contribute 
to higher mortality in hypertensive patients  [13, 14] . In 
this respect, hypertension can be a cause of and a sus-
taining and worsening factor in the progression of renal 
disease. Evidence is accumulating that activation of the 
sympathetic nervous system (SNS) could play a major 
role in the progression of CKD  [15, 16] . Enhanced activ-
ity of the SNS has been demonstrated in patients with 
CKD  [16, 17] . This effect is, at least in part, a consequence 
of chronic activation of sympathoexcitatory inputs 
through renal afferent nerves within the failing kidneys 
because it is not seen in patients who have undergone bi-
lateral nephrectomy  [18] .
 In CKD patients, the overall production of NO is de-
creased, which contributes to cardiovascular events and 
further progression of CKD  [19] . Although the mecha-
nisms responsible for decreased NO production are un-
clear, potential explanations are reduced NO availability 
due to a state of increased oxidative stress or uncoupling 
of NO synthase due to cofactor deficiency  [19–21] .
 In a previous study, we demonstrated that EA and MO 
attenuate progression of renal disease by decreasing 
mean arterial pressure (MAP) and proteinuria  [22] . To 
further understand these effects, we evaluated the effects 
of EA and MO on the metabolism of NO and on renal 
sympathetic nerve activity (RSNA) in a rat model of 
CKD.
 Materials and Methods 
 Animals 
 In this study, all experimental procedures were conducted ac-
cording to the National Institutes of Health Guidelines for the Use 
and Care of Laboratory Animals, and the study protocol was ap-
proved by the Ethics in Research Committee of the Federal Uni-
versity of São Paulo (process No. 0720/09). Fifty-six male Wistar 
rats (250–300 g) were obtained from the animal care facility of 
our institution and were housed in a group cage, given access to 
rat chow and water ad libitum and maintained in a temperature-
controlled environment (23  °  C) on a 12-hour light/dark cycle.
 After a week adaptation period, the animals were weighed and 
transferred to metabolic cages kept in a humidity- and tempera-
ture-controlled room for 24 h to collect urine. The following day, 
42 rats were randomly submitted to 5/6th nephrectomy (5/6 NX) 
under anesthesia with ketamine (100 mg/kg i.p.) plus xylazine (10 
mg/kg i.p.). Briefly, after a ventral laparotomy, removal of the 
right kidney and ligation of two branches of the left renal artery 
were performed, resulting in the infarction of two-thirds of the 
left kidney.
 Experimental Protocols 
 The experiments lasted 8 weeks. The study was carried out as 
two independent series of experiments, each composed of four 
groups: (1) control, normal rats; (2) NX, animals submitted to 5/6 
NX only; (3) NX-AS, animals submitted to 5/6 NX and a 20-min 
EA-MO session using sham points twice weekly, and (4) NX-AM, 
animals submitted to 5/6 NX and a 20-min EA-MO session using 
real acupoints twice weekly. In the first series, MAP and RSNA 
measurements were assessed. In the second series, plasma and 
renal NO levels were assessed. Additionally, in both series, serum 
creatinine and urea, 24-hour proteinuria, tail-cuff  blood pressure 
(TBP) and glomerulosclerosis and tubulointerstitial fibrosis were 
analyzed. 
 Electroacupuncture and Moxibustion 
 The localization of acupoints was based on rat anatomical ref-
erences  [23, 24] . A number of papers studying different animal 
species have clearly shown that the location of acupuncture points 
follows a similar distribution in these mammals  [25] . The entire 
treatment consisted of 16 sessions over the course of 8 weeks (20-
min sessions, twice weekly)  [26, 27] , under inhalatory anesthesia. 
The needle used for stimulation was 0.25 mm in diameter, 2 cm 
long and had a stainless steel stem and copper handle. For bilat-
eral points, the positive output lead from the EA apparatus was 
connected to the left acupoint, and the negative terminal was con-
nected to the right acupoint; the polarity between these points was 
continuously alternated.
 The NX-AM group received acupuncture at points located on 
the hind limbs: ST-36  (Zusanli) , KI-3  (Taixi) . In the rat, ST-36 is 
located approximately 1 mm lateral to the tibial tuberosity, where-
as KI-3 is located at the medial border of the tibia, 0.5 mm above 
the medial malleolus; both of these points are easily located by 
manual inspection. The needles were bilaterally inserted at a 
depth of approximately 0.5 mm at ST-36 and just into the skin at 
KI-3 (due to the lack of evident muscle mass under this area) and 
then subjected to EA (20 Hz/1 V; Plexus AP585; VWV Biotherapy; 
Lautz, Brazil) for a period of 20 min. In addition, MO stimulation 
was applied at the BL-23  (Shenshu) acupoint for a period of 2 min, 
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concomitant with the last 2 min of EA application . The stimula-
tion time was the same for both groups. It is worthwhile mention-
ing that these points were mainly chosen because several studies 
reported their effects as anti-inflammatory and cardiovascular 
modulators  [4, 7–9] .
 The NX-AS group received sham acupuncture at points lo-
cated on neighboring skin areas ( ! 1.5 cm from the real acupoints). 
The sham points were localized in regions with nerve distribu-
tions different from those present at ST-36, KI-3 and BL-23. 
 Biochemical and Blood Pressure Studies 
 Urinary protein excretion was measured using the Sensiprot 
Protein Assay Kit (Labtest Diagnostica, Brazil). Serum creatinine 
and urea were measured using the Labtest Creatinine and Urea 
Kits (Labtest Diagnostica). An initial baseline measurement of 
body weight and urine volume was made.
 Indirect blood pressure was monitored in conscious rats with 
the tail-cuff method  [28] (PE300; Narco Bio-Systems).  Three to 
four measurements for each rat were obtained at each time once 
a week during the study. The week TBP was the median obtained 
from those measurements. 
 Renal Sympathetic Nerve Activity 
 For the MAP, the animals were anesthetized with urethane 
(1.2–1.4 g/kg i.p.), and the left femoral artery and vein were can-
nulated. The MAP was measured with a cannula inserted into the 
femoral artery that was connected to an on-line MacLab system 
(ADInstruments, Bella Vista, N.S.W., Australia)  [29] . Supplemen-
tal doses of urethane (10 mg/kg i.p.) were given as necessary to 
maintain an adequate depth of anesthesia, as assessed by the ani-
mals’ lack of response to a noxious toe pinch, a respiratory pattern 
that followed the ventilator, and a stable blood pressure. Body 
temperature was monitored with a rectal probe (Letica Scientific 
Instruments) and was maintained between 36 and 37  °  C by a ther-
mostatically controlled heating pad.
 For the recording of RSNA, the left renal nerve was retroperi-
toneally exposed, placed on bipolar silver electrodes covered with 
mineral oil  [30] . The signal from the renal nerve was displayed on 
an oscilloscope (TDS 220; Tektronix, Beaverton, Oreg., USA) and 
the nerve activity was amplified (gain 20,000, Neurolog; Digi-
timer, Welwyn Garden City, UK), filtered by a band-pass filter 
(50–1,000 Hz) and collected for display and later analysis using a 
PowerLab data acquisition system (ADInstruments). Intravenous 
phenylephrine bolus infusions (10   g/kg) were administered to 
test the barosensitivity of the registered nerve. At the end of the 
experiments, the basal noise level of the renal sympathetic nerve 
was determined by the administration of the ganglion blocker 
hexamethonium (30 mg/kg, i.v.). RSNA was rectified online, in-
tegrated from the raw data obtained for each heart period and 
expressed as volts-seconds. Additionally, the neural activity was 
analyzed offline using the appropriate software (Spike Histo-
gram; ADInstruments). The data are presented as the number of 
spikes per second (pps)  [31] . 
 Nitric Oxide Levels 
 At the end of the study period, animals were euthanized by 
decapitation for blood and renal tissue collection. Blood samples 
were collected in tubes containing EDTA (final concentration
2 m M ) and N-ethylmaleimide (final concentration 5 m M ), imme-
diately centrifuged at +4  °  C (730  g , 5 min) and stored at –80  °  C for 
later analysis. The remnant kidney was rapidly excised, rinsed, 
sectioned and snap frozen in liquid nitrogen, and stored at –80  °  C 
for later analysis.
 Frozen renal tissue samples were cut in small pieces, placed in 
PBS buffer (1: 5 w/v, pH 7.4) containing EDTA (2 m M ) and N-
ethylmaleimide (10 m M ) and then immediately homogenized 
(BBX24  Bullet Blender, New York, USA). Supernatants were col-
lected after centrifugation (15 min, 17,000  g , 4  °  C).
 Plasma and renal NO levels were determined by the chemilu-
minescence method using a Model 280 nitric oxide analyzer 
(Sievers Instruments Inc., Boulder, Colo., USA), which is a sensi-
tive detector for measuring NO based on a gas phase chemilumi-
nescent reaction between NO and ozone. The sensitivity for the 
measurement of NO and its reaction products is approximately
1 pmol  [32] .
 Histopathology 
 Portions of the remnant kidneys were fixed in 10% neutral 
buffered formalin. Paraffin-embedded sections (3   m thick) were 
cut and stained with hematoxylin and eosin (HE), periodic acid-
Schiff ’s reaction and Masson’s trichrome.
 All morphologic evaluations were performed in a blinded 
manner by a single observer. Glomerular damage was evaluated 
on the basis of the percentage of glomeruli that were sclerotic or 
collapsed. Glomerulosclerosis was defined as segmental increases 
in the glomerular matrix, segmental collapse, obliteration of the 
capillary lumina, and accumulation of hyaline, often with a syn-
echial attachment to Bowman’s capsule  [33, 34] . The extents of 
glomerulosclerosis and glomerular collapse were evaluated in 
each kidney by consecutive examination under light microscopy. 
Tubulointerstitial injury was defined as inflammatory cell infil-
tration, tubular dilation and/or atrophy, or interstitial fibrosis 
 [21] . Injuries were examined in at least 20 areas using the follow-
ing scoring system: 0 = changes  ! 10% of the cortex sections; 1+ = 
changes in up to 25% of the cortex sections; 2+ = changes in up to 
50% of the cortex sections; 3+ = changes in  1 50% of the cortex 
sections  [11] .
 Statistical Methods  
 The results are presented as the mean  8 SD. Comparisons 
among different groups were evaluated using multiple analyses of 
variance (ANOVA) followed by a post hoc protected least-signif-
icant difference test. The level of statistical significance was de-
fined as p  ! 0.05.
 Results 
 EA-MO Significantly Reduced Urine Volume, Serum 
Creatinine Levels and Urea Levels 
 As shown in  table 1 , none of the experimental groups 
differed with respect to body weight at 8 weeks. The final 
urine volume was significantly higher compared to the 
starting volume in all of the nephrectomized groups. 
However, comparison of the final urine volume between 
the different groups showed that it was significantly re-
duced in the NX-AM group. 
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 At the conclusion of the experiments, the serum cre-
atinine and urea concentrations were significantly higher 
than the initial concentrations in all nephrectomized 
groups. However, the NX-AM group had significantly 
lower serum creatinine and urea concentrations than the 
other nephrectomized groups (p  ! 0.05).
 EA-MO Significantly Reduced Proteinuria 
 Proteinuria was significantly higher compared to con-
trol rats in all nephrectomized groups ( fig. 1 ). However, 
rats that received EA-MO had significantly lower pro-
teinuria compared to the rats in the other nephrecto-
mized groups (p  ! 0.05). 
 Blood Pressure and RSNA Returned to Normal Values 
in NX-AM Rats 
 At the end of study period, EA and MO treatment sig-
nificantly attenuated the elevation of TBP and MAP (mm 
Hg) in the NX-AM relative to the NX or NX-AS groups
(p  ! 0.05) ( fig. 2 ,  3 ). As shown in  figures 4 and  5 , EA and 
MO treatment significantly reduced RSNA in comparison 
to NX and NX-AS (p  ! 0.05). The animals treated with EA 
and MO had a significant decrease in heart rate (HR) val-
ue compared to the other groups (p  ! 0.05) ( fig. 5 ). Fur-
thermore, there was no significant difference between the 
TBP, MAP and RSNA of the NX-AM and control group. 
 Table 2 shows all the values for MAP, HR and RSNA.
 EA-MO Increased Serum and Renal NO Levels in 
Nephrectomized Animals 
 Rats treated with EA and MO had a significant in-
crease in serum and renal NO levels compared to the oth-
er nephrectomized groups (p  ! 0.01) ( fig. 6 ,  7 ).
 EA-MO Reduced Glomerulosclerosis and 
Tubulointerstitial Fibrosis Indices  
 As shown in  figure 8 , the glomerulosclerosis index 
(GSI) was significantly reduced in the EA-MO group 
Table 1. B aseline and final functional and biochemical parameters
Group (n = 7) Body weight, g D iuresis, ml/24 h Serum urea, mg/dl Ser um creatinine, mg/dl
initial end initial end initial end initial end
NX 27589 31789 1181.5 33.582.9* 40.581.3 92.4811.4* 0.480.2 1.780.4*
NX-AS 27888 322810 1081.1 34.682.7* 40.280.9 95.1819.4* 0.480.3 1.580.2*
NX-AM 28185 317812 1280.5 22.283.6*, + 4081 65.288.7*, + 0.480.3 0.880.2*, +
Control 27487 338810 1181.6 13.581.2 39.581.1 42.381.9 0.480.2 0.480.8
Valu es are the means 8 SD. * p < 0.05 vs. initial parameters; + p < 0.05 vs. final control, NX and NX-AS.
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 Fig. 2. TBP (mm Hg):  *  p  ! 0.01 vs. TBP NX and NX-AS;  +  p  ! 0.05 
vs. TBP NX and NX-AS. 
 Fig. 1. Proteinuria (mg/24 h):  *  p  ! 0.01 vs. proteinuria NX, NX-
AS and NX-AM;  +  p  ! 0.05 vs. proteinuria NX and NX-AS. 
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compared to the other NX groups. In addition, the tubu-
lointerstitial fibrosis index (TFI) grade of the NX-AM 
group was much lower than that of the other NX groups 
( fig. 9 ,  10 ).
 Discussion 
 TCM has been increasingly recognized as an effective 
therapeutic approach in several fields of medicine. MO 
and EA have been used in TCM for centuries in the treat-
ment of various diseases, including cardiovascular dis-
eases and diseases involving hypertensive syndromes  [7, 
35, 36] . Recently, we demonstrated that EA-MO hindered 
the progression of CKD with reduced SBP/MAP and pro-
teinuria  [22] .
 In the present study, we confirmed our previous re-
sults that demonstrated the beneficial effects of EA-MO 
on the progression of renal diseases, whereby treated an-
imals preserved concentration capacity and had normal 
SBP/MAP values, reduced proteinuria, normal serum 
creatinine and urea levels and better histopathological 
parameters. The current study also made significant 
progress by further elucidating the mechanisms of the 
specific effect on SBP/MAP.
 It is already well established that hypertension is very 
common in patients with CKD and plays a key role in the 
progressive deterioration of renal function. Traditionally, 
hypertension in CKD was viewed as largely volume-de-
pendent, but now there is increasing evidence that the 
activation of the SNS often accompanies CKD and, there-
fore, could contribute to elevation of arterial pressure,
including its influence on fluid retention. The beneficial 
effect of EA-MO on blood pressure has been confirmed 
by several clinical and experimental studies described in 
the literature  [7, 35–41] .
 Experimental evidence suggests that different patho-
physiological mechanisms contribute to the progression 
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 Fig. 4. RSNA (pps):  *  p  ! 0.05 vs. RSNA NX and NX-AS;  +  p  ! 0.05 
vs. RSNA NX and NX-AS. 
 Table 2.  M AP, HR, RSNA and NO levels 
Group MAP
mm Hg
HR
bpm
RSNA
pps
Renal NO
M
Serum NO
M
NX 187.5822.2 469836 211846.5 62.588.9 66813.7
NX-AS 172.3815.2 473828 170.1828.2 82.689.6 60814.7
NX-AM 127817.7+ 384855+ 131812.2+ 152845.5+ 163842.2+
Control 109.786.7* 481852* 12285.5* 104818.6* 120815.2*
V alues are the means 8 SD. * p < 0.05 vs. NX and NX-AS; + p < 0.05 vs. NX and NX-AS.
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of renal disease, including hypertension  [42] , sympathetic 
activation, renin-angiotensin-aldosterone system activa-
tion, proteinuria, oxidative stress, inflammatory cell in-
filtration and action of various mediators and growth fac-
tors and cytokines, including NO and TGF-  1  [1, 43, 44] .
 Sympathetic activation plays an important and dis-
tinctive role in hypertension and target organ damage 
associated with CKD. Experimental studies with 5/6 NX 
rats showed an increase in renal sympathetic activity by 
increasing the production of plasma norepinephrine, lo-
cal release of noradrenaline and AII  [13, 45] . Consistent 
with these studies, our nephrectomized animals without 
treatment had a significant increase in RSNA when com-
pared with control animals. On the other hand, animals 
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from experimental group rats by Masson’s 
trichrome staining: NX ( a ), NX-AS ( b ),
NX-AM ( c ) and control ( d ). Treatment 
with EA-MO ( c ) had significantly less re-
nal injury and widespread glomeruloscle-
rosis and tubulointerstitial injury can be 
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Masson’s trichrome.  ! 40. 
C
o
lo
r v
er
si
o
n 
av
ai
la
b
le
 o
n
lin
e
D
ow
nl
oa
de
d 
by
: 
19
8.
14
3.
56
.3
3 
- 1
0/
22
/2
01
5 
4:
08
:2
0 
PM
 Paterno et al.
 
Kidney Blood Press Res 2012;35:355–364362
treated with EA-MO presented RSNA values in the
normal range. Accordingly, Campese et al.  [45] showed 
that remnant kidney rhizotomy promoted retardation
of CKD with decreased MAP and histological improve-
ment. Furthermore, patients with hypertension and 
non-dialysis CKD have been shown to exhibit hyperac-
tivity of the SNS by using direct detection of peripheral 
sympathetic activity with microneurography and by 
high plasma levels of norepinephrine  [16] . Thus, reduc-
tion in sympathetic activity may assist in antihyperten-
sive treatment  [46] and in CKD. Recently, Schlaich et al. 
 [47] suggested that renal sympathetic nerve ablation ap-
peared to be a logical therapeutic approach for treatment 
of hypertension.
 The available data suggest that afferent signals from 
diseased kidneys to integrative structures in the brain re-
sult in activation of sympathetic outflow, stimulation of 
the renin-angiotensin-aldosterone system and altera-
tions in the  L -arginine/NO pathway and aggravation of 
hypertension  [48] . In the central nervous system, the ros-
tral ventrolateral medulla (RVLM) is an important part 
of the sympathetic efferent limb of cardiovascular reflex 
activity and, as such, it is important in maintenance of 
arterial blood pressure  [31] . Interestingly, in many of 
these studies, EA appears to inhibit sympathetic effects 
by inhibition of sympathoexcitatory RVLM neurons  [49–
51] . In a series of very important experimental studies, 
Longhurst and colleagues  [35, 52, 53] showed that EA in-
hibition of cardiovascular sympathetic neurons is medi-
ated by a complex central nervous system response which, 
in turn, inhibits the activity of pre-motor sympathetic 
neurons in the RVLM.
 Another possible explanation for the SNS modulation 
by EA-MO is an activation of opioid receptors in the cen-
tral nervous system and increased production and secre-
tion of endogenous opioids, serotonin, catecholamines, 
angiotensin II, and NO pathway  [5, 8, 54] . Additionally, 
glutamate, acetylcholine, opioids, GABA, nociceptin, se-
rotonin and endocannabinoids all appear to participate 
in the EA hypotensive response  [35, 55, 56] .
 The hypertension pathogenesis has also been associ-
ated with decreased NO production, which mediates ar-
teriolar vasodilatation, reduces peripheral resistance, and 
lowers blood pressure. In the present study, we found that 
nephrectomized rats presented lower serum and renal 
NO levels in comparison to control rats. In contrast, EA-
MO treatment increased serum and renal NO levels above 
the normal levels. Consistent with our findings, it has 
been shown that total NO production is decreased due to 
impaired endothelial and renal NO production in CKD; 
thus, NO deficiency could play a role in CKD progression 
 [57–59] . In addition, several studies have demonstrated 
that EA can modulate the production of NO synthases in 
hypertensive animals  [60–62] .
 Taken together, we postulate that the reduced RSNA 
and the increased serum and renal NO levels caused by 
EA-MO treatment exerted an evident beneficial influ-
ence on SBP/MAP. This effect associated with reduced 
proteinuria improved renal function of EA-MO-treated 
animals, as demonstrated by the reduction of glomerulo-
sclerosis serum creatinine and urea, preserved urinary 
concentration capacity and lower degrees of glomerular 
and tubular injury. 
 The value of EA and MO as effective therapeutic tools 
has been confirmed by numerous studies in recent de-
cades. Scientific advances have clarified the neurobiolog-
ical basis of both EA and MO, mainly through experi-
mental models using EA at the acupoint ST-36  [27, 63] . To 
our knowledge, our work was the first to use EA at both 
ST-36 and KI-3 combined with MO in BL-23. However, 
further studies are needed in order to consolidate TCM 
concepts in nephrology as a valid adjunct treatment for 
CKD.
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